The Technical Analyst
Edgewise Therapeutics, [EWTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Edgewise Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-5.89% $15.65
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 457.18 mill |
| EPS: | -1.570 |
| P/E: | -9.97 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 93.11 mill |
| Avg Daily Volume: | 0.947 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.97 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.70x |
| Company: PE -9.97 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.266 (-91.91%) $-14.38 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 14.62 - 16.68 ( +/- 6.59%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-07 | Moore John R | Sell | 17 993 | Stock Option (Right to Buy) |
| 2024-02-08 | Moore John R | Sell | 3 813 | Stock Option (Right to Buy) |
| 2024-02-09 | Moore John R | Sell | 8 029 | Stock Option (Right to Buy) |
| 2024-02-07 | Moore John R | Buy | 17 993 | Common Stock |
| 2024-02-09 | Moore John R | Buy | 8 029 | Common Stock |
| INSIDER POWER |
|---|
| 74.50 |
| Last 97 transactions |
| Buy: 6 997 164 | Sell: 659 479 |
Forecast:
16:00 - $15.65
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.65
Forecast 2: 16:00 - $15.65
Forecast 3: 16:00 - $15.65
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.65 (-5.89% ) |
| Volume | 0.665 mill |
| Avg. Vol. | 0.947 mill |
| % of Avg. Vol | 70.20 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EWTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $19.98 | N/A | Active |
|---|
EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Latest Press Releases
2024-04-15 16:05:00 - Press Release
Edgewise Therapeutics Announces Positive Two-year Topline Results From The Arch Open Label Trial Of Sevasemten (edg-5506) In Adults With Becker Muscular Dystrophy (becker)
Boulder, colo.--(business wire)--edgewise therapeutics, inc., (nasdaq: ewtx), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the arch trial. arch is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (pk) and functional measures with sevasemten (edg-5506) in adults with becker. sevasemten is an orally administered small molecule designed to prevent contraction-induced.
2024-03-28 08:00:00 - Press Release
Edgewise Therapeutics Announces Upcoming Podium Presentation At The American College Of Cardiology's 2024 Annual Scientific Session
Boulder, colo.--(business wire)--edgewise therapeutics, inc. (nasdaq: ewtx), a leading muscle disease biopharmaceutical company, today announced that the company will present data on edg-7500 at the american college of cardiology's annual scientific session (acc.24). edg-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hcm and other diseases of diastolic dysfunc.
2024-03-27 08:00:00 - Press Release
Edgewise Therapeutics To Present At The Cantor Virtual Muscular Dystrophy Symposium On April 2, 2024
Boulder, colo.--(business wire)--edgewise therapeutics, inc., (nasdaq: ewtx), a leading muscle disease biopharmaceutical company, today announced that management will present at the cantor virtual muscular dystrophy symposium on tuesday, april 2, 2024, at 2:20 pm et. the presentation will be webcast live; a link for the webcast can be found on the edgewise events page and will be accessible for replay following the presentation. it is recommended that users connect to the webcast several minute.
2024-02-28 08:00:00 - Press Release
Edgewise Therapeutics To Present On Edg-5506 For The Treatment Of Becker Muscular Dystrophy At The 2024 Mda Clinical And Scientific Conference
Boulder, colo.--(business wire)--edgewise therapeutics, inc., (nasdaq: ewtx), a leading muscle disease biopharmaceutical company, today announced that the company will present data on edg-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the muscular dystrophy association (mda) clinical and scientific conference. the conference will take place at the hilton orlando in orlando, fl from march 3-6, 2024. details of the edg.
2024-02-13 08:00:00 - Press Release
Edgewise Receives U.s. Fda Fast Track Designation For Edg-5506 For The Treatment Of Duchenne Muscular Dystrophy (duchenne)
Boulder, colo.--(business wire)--edgewise therapeutics, inc., (nasdaq: ewtx), a leading muscle disease biopharmaceutical company, today announced that the u.s. food and drug administration (fda) has granted fast track designation for edg-5506 for the treatment of duchenne. edg-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including duchenne and becker muscular dystrophy (becker). the fda previously gran.
Latest News
2024-02-26 10:56:08 - Zacks Investment Research
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-11 14:55:58 - InvestorPlace
Insider Favorites: 7 Stocks with Bullish Buying Signals
While investors shouldn't get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it's difficult to tell what insider selling means.
2024-02-09 10:56:17 - Zacks Investment Research
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-27 13:09:38 - 24/7 Wall Street
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.
2024-01-24 10:56:03 - Zacks Investment Research
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-22 15:11:16 - Zacks Investment Research
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
2023-12-28 15:00:21 - Seeking Alpha
Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing
Edgewise Therapeutics, Inc. interim results from the phase 2 LYNX study, using EDG-5506 for the treatment of children ages 4 to 9 with DMD, are expected first half of 2024. Expansion opportunity exists to use EDG-5506 for the treatment of children and adolescent DMD patients ages 6 to 14 who have previously already been treated with gene therapy. It is expected that the global Duchenne Muscular Dystrophy treatment market size is expected to reach $3.89 billion by 2028.
2023-12-26 17:21:16 - CNBC Television
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
2023-09-05 11:17:13 - Zacks Investment Research
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 327.9% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-05-02 08:00:00 - Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today that management will participate in fireside chats at two upcoming investor conferences: BofA Securities 2022 Healthcare Conference Presentation: Tuesday, May 9, 2023 at 8:55 am PDT (11:55 am ET) RBC Capital Markets Global Healthcare.